Avanir says FDA approval in November for migraine treatment unlikely

Nov 7 (Reuters) - Avanir Pharmaceuticals Inc said it was unlikely that its experimental migraine drug-device would win U.S. Food and Drug Administration approval by the scheduled timeline, sending...

from Reuters: Hot Stocks http://ift.tt/1sel9kI